Chris Viehbacher, Biogen CEO (Photo by Suzanne Kreiter/The Boston Globe via Getty Images)

8 take­aways from Bio­gen’s Q1 up­date: A ‘dif­fi­cult’ launch for Leqem­bi, a $103M vouch­er and a fo­cus on new li­cens­ing deals

Bio­gen’s lead­ers de­fend­ed their Ei­sai-part­nered Leqem­bi dur­ing a first-quar­ter earn­ings up­date on Wednes­day, say­ing the Alzheimer’s treat­ment is on a path to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.